PDS Biotechnology PDSB
NASDAQ PDSB
$0.75 +0.04 (+5.63%)
At close: Oct 2, 2026 · 4:00 PM EDT

PDS Biotechnology (PDSB) Gains from Sales and Divestitures (2016)

Updated

PDS Biotechnology (PDSB) posted Gains from Sales and Divestitures of -$310,951 for FY2019.

Analysis

PDS Biotechnology (PDSB) Gains from Sales and Divestitures (2016) Analysis & Trends

  • The FY2019 figure stands as the highest annual Gains from Sales and Divestitures since FY2016.
  • Business Quant data shows PDSB's Gains from Sales and Divestitures at -$102,788 in FY2016.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 PDS Biotechnology 41.94 Mn 41.94 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2016 1.00
API Access

PDS Biotechnology Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=PDSB&period=max&api_key=YOUR_API_KEY